The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study
Open accessAbstract
Background: Proteins pathogenic in Alzheimer's disease (AD) were extracted from neurally derived blood exosomes and quantified to develop biomarkers for the staging of sporadic AD. Methods: Blood exosomes obtained at one time‐point from patients with AD (n = 57) or frontotemporal dementia (FTD) (n = 16), and at two time‐points from others (n = 24) when cognitively normal and 1 to 10 years later when diagnosed with AD were enriched for neural sources by immunoabsorption. AD‐pathogenic exosomal proteins were extracted and quantified by enzyme‐linked immunosorbent assays. Results: Mean exosomal levels of total tau, P‐T181‐tau, P‐S396‐tau, and amyloid β 1–42 (Aβ1–42) for AD and levels of P‐T181‐tau and Aβ1–42 for FTD were significantly higher than for case‐controls. Step‐wise discriminant modeling incorporated P‐T181‐tau, P‐S396‐tau, and Aβ1–42 in AD, but only P‐T181‐tau in FTD. Classification of 96.4% of AD patients and 87.5% of FTD patients was correct. In 24 AD patients, exosomal levels of P‐S396‐tau, P‐T181‐tau, and Aβ1–42 were significantly higher than for controls both 1 to 10 years before and when diagnosed with AD. Conclusions: Levels of P‐S396‐tau, P‐T181‐tau, and Aβ1–42 in extracts of neurally derived blood exosomes predict the development of AD up to 10 years before clinical onset.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Altered EV profiles are detectable at prodromal stages such as MCI, supporting their value as early biomarkers. 26 , 27”
From Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease (2026) · cites this paper as [26]
In the citing paper
“Exosomes isolated from the brain, cerebrospinal fluid (CSF), and plasma of AD patients and/or AD animal models contain pathologic Aβ and tau [73, 75–77].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [77]
In the citing paper
“Interestingly, increased levels of exosome-associated tau have been found by some groups in the CSF and blood of individuals with AD and FTDs [55, 117].”
From Glial contributions to neurodegeneration in tauopathies (2017) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationResearch criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Melnick, V. L., & Dubler, N. N. (1985) · Contemporary Issues in Biomedicine, Ethics, and Society · doi:10.1007/978-1-4612-5174-3 · Cited by 1,986
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
Plasma phospholipids identify antecedent memory impairment in older adults
Mapstone, M. E., Cheema, A. K., Fiandaca, M. S., Zhong, X., Mhyre, T. R., MacArthur, L. H., Hall, W. J., Fisher, S. G., Peterson, D. R., Haley, J. M., et al. (2014) · Nature Medicine · doi:10.1038/nm.3466 · Cited by 1,060
Self-citationSaman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Saman, S., Jackson, B., McKee, A. C., Alvarez, V. E., Lee, N. C. Y., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277061 · Cited by 985
Maruyama, M., Shimada, H., Suhara, T., Shinotoh, H., Ji, B., Maeda, J., Zhang, M.-R., Trojanowski, J. Q., Lee, V. M.-Y., Ono, M., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.037 · Cited by 760
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“Increases in brain tissue oligomeric amyloid b (Ab) peptides and phosphorylated tau (P-tau) detected by central nervous system (CNS) imaging and in cerebrospinal fluid (CSF) levels of soluble Ab1–42 and P-tau have been documented years before the signs of AD [3–6].”
BackgroundGraff‐Radford, N. R., Crook, J. E., Lucas, J. A., Boeve, B. F., Knopman, D. S., Ivnik, R. J., Smith, G. E., Younkin, L. H., Petersen, R. C., & Younkin, S. G. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.354 · Cited by 452
Self-citationPlasma tau levels in Alzheimer's disease
Zetterberg, H., Wilson, D. H., Andréasson, U., Minthon, L., Blennow, K., Randall, J., & Hansson, O. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt163 · Cited by 385
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
(2012) · New England Journal of Medicine · doi:10.1056/nejmx120056 · Cited by 385
Hansson, O., Zetterberg, H., Vanmechelen, E., Vanderstichele, H., Andréasson, U., Londos, E., Wallin, A., Minthon, L., & Blennow, K. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.03.027 · Cited by 282
Emerging roles of exosomes in neuron-glia communication
Frühbeis, C., Fröhlich, D., & Krämer-Albers, E.-M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00119 · Cited by 275
Age but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258
Association of Plasma β-Amyloid Level and Cognitive Reserve With Subsequent Cognitive Decline
Yaffe, K. S. (2011) · JAMA · doi:10.1001/jama.2010.1995 · Cited by 245
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Fluid biomarkers in Alzheimer’s disease – current concepts
Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 221
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study
López, O. L., Kuller, L. H., Mehta, P. D., Becker, J. T., Gach, H. M., Sweet, R. A., Chang, Y., Tracy, R. P., & DeKosky, S. T. (2008) · Neurology · doi:10.1212/01.wnl.0000306696.82017.66 · Cited by 158
Thinking laterally about neurodegenerative proteinopathies
Golde, T. E., Borchelt, D., Giasson, B. I., & Lewis, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66029 · Cited by 126
Potential Contribution of Exosomes to the Prion-Like Propagation of Lesions in Alzheimer’s Disease
Vingtdeux, V., Sergeant, N., & Buée, L. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00229 · Cited by 116
Modeling human neurodegenerative diseases in transgenic systems
Sosa, M. A. G., Gasperi, R. D., & Elder, G. A. (2011) · Human Genetics · doi:10.1007/s00439-011-1119-1 · Cited by 114
Seppälä, T. T., Herukka, S., Hänninen, T., Tervo, S., Hallikainen, M., Soininen, H. S., & Pirttilä, T. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.205757 · Cited by 98
Takeda, S., Hashimoto, T., Roe, A. D., Hori, Y., Spires‐Jones, T. L., & Hyman, B. T. (2013) · The FASEB Journal · doi:10.1096/fj.13-229666 · Cited by 74
Aging enhances release of exosomal cytokine mRNAs by Aβ 1‐42 ‐stimulated macrophages
Mitsuhashi, M., Taub, D. D., Kapogiannis, D., Eitan, E., Zukley, L. M., Mattson, M. P., Ferrucci, L., Schwartz, J. B., & Goetzl, E. J. (2013) · The FASEB Journal · doi:10.1096/fj.13-238980 · Cited by 70
Self-citationSanfeliu, V., Elías, A. R., Figueras, D., Verdura, T., Gelabert, M. L., Pique, J., Torra, J. E., Esteve, N., & Nadal, M. J. N. (1993) · PubMed · Cited by 61
Diagnostic Utility of CSF Tau and Aβ42 in Dementia: A Meta‐Analysis
Agarwal, R., & Tripathi, C. B. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/503293 · Cited by 16
Cited by
Sorted by citations
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710
Depletion of microglia and inhibition of exosome synthesis halt tau propagation
Asai, H., Ikezu, S., Tsunoda, S., Medalla, M., Luebke, J., Haydar, T., Wolozin, B., Butovsky, O., Kügler, S., & Ikezu, T. (2015) · Nature Neuroscience · doi:10.1038/nn.4132 · Cited by 1,591
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Metadata
- Authors
- Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., & Goetzl, E. J.
- Affiliations
- Georgetown University Medical Center (US)
- National Institute on Aging (US)
- University of Rochester Medicine (US)
- University of California San Francisco Medical Center (US)
- University of Kentucky (US)
- Mayo Clinic (US)
- Corresponding author
- Goetzl, Edward J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2014-08-14
- Volume
- 11
- Issue
- 6
- Pages
- 600
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC4329112
- OpenAlex
- W1995903088
- Cited by
- 959
- References
- 31
- Citations by year
- 2026: 77 · 2025: 91 · 2024: 109 · 2023: 86 · 2022: 115 · 2021: 106 · 2020: 105 · 2019: 93 · 2018: 46 · 2017: 50 · 2016: 50 · 2015: 24 · 2014: 3
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute on Aging (NIA RO1AG030753)
- National Institutes of Health (UK ADC P30 AG028383)
- Genentech
- Alzheimer's Association
- Association for Frontotemporal Degeneration
- Alzheimer's Drug Discovery Foundation
- Pfizer
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Keywords
- preclinical Alzheimer's disease, blood exosomes
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, Severity of Illness Index, Time Factors, Biomarkers, Discriminant Analysis, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Exosomes, Frontotemporal Dementia, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
